Sanofi Net Profit Margin 2012-2026 | SNY
Current and historical net profit margin for Sanofi (SNY) from 2012 to 2026. Net profit margin can be defined as net Income as a portion of total sales revenue. Sanofi net profit margin for the three months ending March 31, 2026 was .
| Sanofi Net Profit Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM Net Income | Net Margin |
| 2026-03-31 | $54.84B | $8.76B | 15.97% |
| 2025-12-31 | $52.85B | $8.84B | 16.73% |
| 2025-09-30 | $46.78B | $10.21B | 21.83% |
| 2025-06-30 | $46.96B | $10.03B | 21.36% |
| 2025-03-31 | $47.02B | $6.76B | 14.37% |
| 2024-12-31 | $47.92B | $6.02B | 12.55% |
| 2024-09-30 | $53.03B | $4.91B | 9.27% |
| 2024-06-30 | $51.29B | $4.57B | 8.91% |
| 2024-03-31 | $50.68B | $4.93B | 9.73% |
| 2023-12-31 | $50.27B | $5.84B | 11.63% |
| 2023-09-30 | $49.01B | $9.68B | 19.75% |
| 2023-06-30 | $48.42B | $9.02B | 18.63% |
| 2023-03-31 | $48.20B | $8.71B | 18.06% |
| 2022-12-31 | $47.82B | $8.82B | 18.44% |
| 2022-09-30 | $48.72B | $8.33B | 17.09% |
| 2022-03-31 | $34.76B | $6.88B | 19.78% |
| 2021-09-30 | $35.03B | $6.90B | 19.70% |
| 2021-03-31 | $43.57B | $7.99B | 18.34% |
| 2020-09-30 | $42.75B | $7.39B | 17.29% |
| 2020-03-31 | $41.19B | $6.36B | 15.44% |
| 2019-09-30 | $41.49B | $4.98B | 12.00% |
| 2019-03-31 | $41.50B | $4.86B | 11.70% |
| 2018-03-31 | $41.43B | $4.71B | 11.36% |
| 2017-12-31 | $40.92B | $9.53B | 23.30% |
| 2017-09-30 | $40.25B | $9.90B | 24.58% |
| 2017-06-30 | $39.59B | $9.92B | 25.06% |
| 2017-03-31 | $39.14B | $10.09B | 25.77% |
| 2016-12-31 | $38.41B | $5.21B | 13.57% |
| 2016-09-30 | $39.27B | $6.19B | 15.75% |
| 2016-06-30 | $39.37B | $5.76B | 14.63% |
| 2016-03-31 | $41.16B | $5.52B | 13.40% |
| 2015-09-30 | $42.97B | $4.90B | 11.40% |
| 2015-06-30 | $43.92B | $4.59B | 10.45% |
| 2014-06-30 | $44.70B | $5.57B | 12.45% |
| 2013-06-30 | $45.22B | $6.39B | 14.12% |
| 2012-06-30 | $46.75B | $8.61B | 18.41% |
| 2012-03-31 | $47.10B | $8.56B | 18.17% |
| 2011-12-31 | $47.27B | $9.33B | 19.74% |
| 2011-09-30 | $45.65B | $8.04B | 17.61% |
| 2011-06-30 | $44.35B | $7.45B | 16.81% |
| 2011-03-31 | $42.93B | $8.22B | 19.15% |
| 2010-12-31 | $41.26B | $8.24B | 19.96% |
| 2010-09-30 | $41.28B | $9.30B | 22.53% |
| 2010-06-30 | $41.42B | $10.37B | 25.04% |
| 2010-03-31 | $41.35B | $11.38B | 27.52% |
| 2009-12-31 | $40.79B | $10.99B | 26.95% |
| 2009-09-30 | $40.53B | $9.57B | 23.62% |
| 2009-06-30 | $39.73B | $8.26B | 20.78% |
| 2009-03-31 | $39.56B | $7.76B | 19.61% |
| 2008-12-31 | $40.89B | $7.76B | 18.99% |
| 2008-09-30 | $41.42B | $9.72B | 23.46% |
| 2008-06-30 | $41.43B | $10.42B | 25.15% |
| 2008-03-31 | $40.37B | $9.21B | 22.82% |
| 2007-12-31 | $39.59B | $8.40B | 21.22% |
| 2007-09-30 | $38.72B | $6.95B | 17.95% |
| 2007-06-30 | $37.43B | $6.45B | 17.24% |
| 2007-03-31 | $36.97B | $7.18B | 19.43% |
| 2006-12-31 | $35.70B | $6.99B | 19.58% |
| 2006-09-30 | $34.55B | $6.79B | 19.65% |
| 2006-06-30 | $34.49B | $6.95B | 20.16% |
| 2006-03-31 | $34.02B | $6.66B | 19.58% |
| 2005-12-31 | $33.98B | $5.54B | 16.31% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $114.048B | $49.347B |
| Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |